BioCryst Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BioCryst Pharmaceuticals, Inc.
Chinese CAR-T therapy developer raises new funds to progress pipeline in over-subscribed IPO which ranks as the third-largest globally in the biotech sector to date this year.
WTO director general says pharma could have done more on voluntary licensing for COVID-19 vaccines and also calls for better transparency of pricing and contracts to ensure “a level playing field” when it comes to saving lives.
Immersive technologies are becoming a reality in the OR. The second part of Medtech Insight’s series on the “Future of Surgery” introduces innovators of VR simulation tech, AR surgery platforms and AR Smart Glasses, and provides insights from world-renowned AR surgeons.
Flagship, the investor behind COVID-19 success story Moderna, has raised a huge fund that will be used to create and develop its own companies before spinning them off.
- Other Names / Subsidiaries
- BioCryst Pharmaceuticals